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Abstract
Objectives: The EVOLVE 48 study evaluated the safety and effectiveness of the
SYNERGY 48 mm stent for the treatment of long lesions.
Background: Clinical evidence supporting the use of very long stents during percutane-
ous coronary intervention (PCI) is limited. The bioabsorbable polymer SYNERGY stent
has shown good long-term data in a broad population of patients undergoing PCI.
Methods: Patients with lesion length >34- ≤44 mm and reference vessel diameter
(RVD) ≥2.5- ≤ 4.0 mm were enrolled in this prospective, multicenter, single-arm
study. The primary endpoint was 12-month target lesion failure (TLF; composite of
target lesion revascularization [TLR], target-vessel myocardial infarction [TV-MI], or
cardiac death) compared to a prespecified performance goal (PG).
Results: A total of 100 patients with mean lesion length of 35.34 ± 7.15 mm
(26 patients with lesion length > 40 mm) and mean RVD 2.72 ± 0.44 mm were
enrolled. Moderate to severe calcification was present in 30% of the patients and
89% had pre-TIMI flow grade 3. The rates of technical and clinical procedural success
were 100%. One-year TLF was observed in 4.1% patients compared to a prespecified
PG of 19.5% (95% upper confidence bound = 9.1%; p < 0.0001). Cardiac death and
TLR were each observed in one patient, and TV-MI in two patients treated with SYN-
ERGY 48 mm stent. Between the 1-2-year timeframe, TV-MI occurred in one addi-
tional patient. None of the patients experienced a definite or probable stent
thrombosis through 2 years.
Conclusions: PCI of long coronary lesions with the 48 mm SYNERGY stent demon-
strated good procedural and clinical outcomes through 2 years, supporting its clinical
safety and efficacy.
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1 | INTRODUCTION
The introduction of drug-eluting stents (DES) that release antip-
roliferative drugs into the arterial wall to inhibit neointimal prolif-
eration and inflammation, has revolutionized percutaneous
coronary intervention (PCI). Due to a reduced risk of restenosis
and stent thrombosis (ST), DES are now the recommended treat-
ment of choice for obstructive coronary artery disease (CAD).1
Additionally, the improved design characteristics of new genera-
tion DES have allowed their widespread use in complex CAD,
including long coronary artery lesions that represent a significant
proportion of PCI cases.2,3
Treatment of long lesions typically requires multiple stents
with variable overlap, which may contribute to an increased risk of
restenosis, side-branch occlusion, and ST.4-6 The availability of
longer-length stents may reduce the need for multiple overlapping
stents. Studies suggest that implantation of one long stent instead
of two or more shorter overlapping stents reduces both proce-
dural cost and time. Consequently, additional patient benefit
accrues from reduced contrast agent use and reduced radiation
exposure.7,8
The new generation SYNERGY stent combines several design
features, including an abluminal everolimus coating (eluted in
90 days) and bioabsorbable poly(D,L-lactide-co-glycolide) (PLGA)
polymer (completely degraded within 4 months), that may improve
arterial healing and reduce the occurrence of late/very late ST, as
well as the requirement for prolonged dual antiplatelet therapy
(DAPT).9,10 Clinical data from randomized controlled trials and large
observational studies have shown promising results with SYNERGY,
including low rates of revascularization and thrombotic events.10-14
The EVOLVE 48 study evaluated the clinical efficacy and safety of
the 48 mm SYNERGY stent in patients undergoing PCI for long cor-
onary lesions.
2 | METHODS
EVOLVE 48 was a prospective, multicenter, open label, single-arm
study that enrolled 100 patients at 15 clinical sites in the United
States, Europe, and New Zealand. The study was conducted in
accordance with ISO 14155:2011 Clinical Investigation of Medical
Devices for Human Subjects—Good Clinical Practice (GCP), the Dec-
laration of Helsinki, and all applicable local regulations. Prior to
enrollment, all patients provided written informed consent and the
Institutional Review Board at each site approved the study protocol.
The study is registered at www.clinicaltrials.gov under identifier
NCT03350542.
2.1 | Device description
A detailed description of the SYNERGY stent has been published else-
where.15 In brief, SYNERGY is a thin strut (74–81 μm), platinum chro-
mium metal alloy stent with an ultrathin (4 μM) bioabsorbable polymer
designed to release everolimus (100 μm/cm2) on the abluminal side
only. Drug release and polymer degradation are completed in parallel
within 4 months,16 leaving behind a biocompatible bare metal platform.
2.2 | Study design and procedure
Patients ≥18 years of age were eligible if they had either (1) symptomatic
CAD with coronary stenosis ≥70%, abnormal fractional flow reserve,
elevated cardiac biomarkers or an abnormal stress or imaging stress test,
or (2) silent ischemia based on abnormal fractional flow reserve (FFR),
abnormal stress or imaging stress test, or elevated biomarkers prior to
the procedure. The main angiographic inclusion criteria were lesion
length >34 to ≤44 mm in a native coronary artery with a reference ves-
sel diameter (RVD) ≥2.5 to ≤4.0 mm (both by visual estimation), target
lesion with visually estimated stenoses ≥50% and < 100% and Throm-
bolysis in Myocardial Infarction (TIMI) flow >1, and successful
predilatation of the target lesion. Patients with acute STEMI, left main
or saphenous vein graft lesions, chronic total occlusion, in-stent resteno-
sis, and bifurcations requiring >1 stent were excluded. Eligible patients
who met the inclusion criteria were enrolled and treated with a single
48 mm SYNERGY stent. Treatment of one nontarget lesion in one non-
target vessel was allowed during the index procedure.
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibi-
tor was prescribed following PCI for at least 6 months (12 months in
patients with acute coronary syndrome). All patients were required to
take aspirin through 2 years of follow-up. Clinical follow-up was
required in hospital, at 30 days, 6- and 12-months following PCI, and
then at 2 years. Protocol-specified coronary angiography assessment
was required during index procedure, but not at follow up.
2.3 | Study endpoints
The primary endpoint was the rate of 12-month target lesion failure (TLF),
defined as the composite of any ischemia-driven revascularization of the
target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave)17
related to the target vessel, or any cardiac death. Secondary clinical end-
points evaluated at both 1- and 2 years included target vessel failure (TVF;
composite of ischemia-driven target vessel revascularization [TVR], target
vessel-relatedMI [TV-MI] or death), all-cause death, individual components
of TLF, and Academic Research Consortium defined stent thrombosis
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(ST).18 ST, TVR, MI, and death were adjudicated by an independent clinical
events committee (CEC). Technical successwas defined as successful deliv-
ery and deployment of the study stent into the target vessel, without bal-
loon rupture or stent embolization, and postprocedure diameter stenosis of
<30%with TIMI 3 flow in the target lesion (as visually assessed by the phy-
sician). Clinical procedural success was defined as postprocedure diameter
stenosis <30%, TIMI 3 flow in the target lesion without the occurrence of
in-hospitalMI, cardiac death or TVR. All procedural angiogramswere evalu-
ated by an independent angiographic core laboratory (Beth Israel Deacon-
essMedical Center, Boston,MA).
2.4 | Data availability statement
The data for this clinical trial may be made available to other
researchers in accordance with the Boston Scientific Corporation
(BSC) Data Sharing Policy (http://www.bostonscientific.com/en-US/
data-sharing-requests.html).
2.5 | Statistical methods
The study was powered to assess the primary endpoint of 12-month
TLF compared to a prespecified performance goal of 19.5%, which
was based on EVOLVE II-like patients with lesion length >34 and
≤44 mm from PROMUS Element Plus US Post-Approval Study19 and
PE-Prove Study.20 The expected 12-month TLF rate of 9.2% was
based on results from EVOLVE II RCT15 for SYNERGY and assumed a
relative 20% increase in rates for every 10 mm increase in mean lesion
length. A one-group Clopper–Pearson exact test was used to test
whether the 12-month TLF rate for SYNERGY was less than the per-
formance goal. If the p-value was <0.05 in both perprotocol and
intent-to-treat (ITT) populations, SYNERGY 48 mm stent would be
concluded to successfully meet the performance goal with respect to
the 12-month TLF rate. This corresponds to the one-sided 95% upper
confidence bound (UCB) on the observed 12-month TLF rate from
SYNERGY being less than the performance goal. Given a performance
goal of 19.5% and one-sided test significance level of 0.05, a minimum
of 95 patients would provide at least 80% power for TLF after
adjusting for attrition (5%). Discrete variables were reported as per-
centages (%) and continuous variables as mean ± standard deviation.
Clinical outcomes were evaluated by the Kaplan–Meier method. Con-
fidence intervals were evaluated using normal approximation. Statisti-
cal analyses were conducted using SAS® Version 9.0 or later (SAS
Institute, Cary, NC, USA).
3 | RESULTS
3.1 | Patients and enrollment
The EVOLVE 48 study enrolled 100 patients between April 2018 and
January 2019 at 15 clinical sites (Figure 1). Baseline clinical and lesion
characteristics are listed in Tables 1 and 2. The average age was
65 years, 40% were female, 27% had medically treated diabetes
mellitus, 14% had unstable angina and 24% had MI diagnosed prior to
the index PCI (Table 1). All patients had lesion length >34 mm based
on site assessment, which was one of the main eligibility criteria for
inclusion. Angiographic core lab adjudicated mean lesion length and
RVD were 35.34 ± 7.15 and 2.72 ± 0.44 mm, respectively (Table 2). A
total of 20 patients had a nontarget lesion treated during the index
procedure. Mean stent length implanted was 50.96 ± 7.25 mm
(Table 3). Site-reported technical and clinical procedural success rates
were 100%. The core lab confirmed the angiographic data for site-
reported clinical procedural success. Postprocedural angiographic
results were available in all 100 lesions (Table 3). Mean postprocedure
in-stent diameter stenosis was 9.74% ± 7.19% and minimum lumen
diameter was 2.47 ± 0.40 mm. Additional angiographic outcomes are
shown in Table 3. At 2 years follow-up, 91% patients were on aspirin
(Figure 2). DAPT usage decreased from 99% postimplantation to 72%
at 1-year and 41% at 2 years.
3.2 | Clinical outcomes
The trial primary endpoint of 1-year TLF analyzed by ITT and
perprotocol was observed in 4.1% of SYNERGY 48 mm treated
patients and the one-sided 95% UCB was 9.1%, significantly less than
the performance goal of 19.5% (p < 0.0001; Figure 3). Cardiac mortal-
ity was reported in one patient (318 days postprocedure). Two
patients had a non-Q-wave-MI related to the study stent (111- and
292-days postprocedure) and one patient underwent TLR that was
treated with PCI (259 days postprocedure).
F IGURE 1 EVOLVE 48 study enrollment and follow-up.
DS, diameter stenosis; ISR, in-stent restenosis target lesion; LM, left
main; RVD, reference vessel diameter; STEMI, ST-segment elevation
myocardial infarction; SVG, saphenous vein graft target lesion; TIMI,
thrombolysis in myocardial infarction
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Kaplan–Meier curves for the occurrence of TLF and its individual
components (cardiac death, MI and TVR) through 2 years are shown
in Figure 4. One additional patient experienced target vessel related
non-Q-wave MI between the 1-2-year timeframe (624 days
postprocedure). None of the patients experienced a definite or proba-
ble ST through 2 years. Secondary clinical outcomes at 2 years
poststent implantation are shown in Table 4.
4 | DISCUSSION
EVOLVE 48, a prospective, single-arm, global study, met the primary end-
point of 1-year TLF in patients with long coronary lesions. Despite the
angiographic complexity of long lesions treated per protocol in EVOLVE
48, the rates of technical and clinical procedural success were 100%. The
2-year rates of TLF, target vessel MI, cardiac death, and TLR remained
relatively low. No ST was observed in any of the patients implanted with
the SYNERGY48 mm stent through 2 years of follow-up.
Long coronary artery lesions constitute a significant proportion of
PCI cases, in which approximately a third of the population need
multiple overlapping stents due to the lesion length exceeding that of
the longest available or deliverable stent.3 Treatment of long lesions is
challenging due to difficult stent deliverability and the need for stent
overlap, which may lead to geographical miss and in-stent resteno-
sis.21 Both stent length and stent overlap are predictors of adverse
clinical outcomes following DES implantation.6 As such, the availabil-
ity of longer-length stents can reduce the need for multiple over-
lapping stents and associated procedural costs as well as adverse
angiographic and clinical outcomes. Further, reduction of the number
of stents used to treat a lesion reduces intervention time, need for
contrast agent, radiation exposure for both the patient and the opera-
tor, and may impact long-term outcomes.3,8
The introduction of new stent technologies with improved design
and antiproliferative drugs eluting from a bioabsorbable polymer may
have decreased the impact of the previously reported association
between stent length and restenosis.3 However, there are limited data
supporting the use of new generation DES with longer stent lengths.
SYNERGY, a newer generation bioabsorbable polymer stent, incorpo-
rates specific design characteristics that enhance deliverability and
facilitate healing. Long-term safety and efficacy of SYNERGY have
been established in a broad population of patients undergoing
PCI.12,14 Data from the present study compare well with those from
previous studies on the SYNERGY stent in patients with moderate
complexity and implanted stent length ≤34 mm.11,14,22 The 1-year
rates of TLF (4.0%), TVR (1.0%) and ST (0.0%) in patients implanted
with the 48 mm SYNERGY stent were similar to or lower than those
TABLE 1 Baseline Clinical Characteristics
Synergy 48
N = 100 patients
Patient Charactersitics







Medically treated diabetes 27.0% (27)




Myocardial infarction 24.0% (23)
Congestive heart failure 8.0% (8)
Stable angina 62.6% (62)
Unstable angina 14.1% (14)




Multivessel disease 42.9% (42)
History of renal disease 10.0% (10)
History of peripheral vascular disease 10.1% (10)
Note: Values are mean ± SD or % (n), Intent-to-treat analysis.
Abbreviations: CABG, coronary artery bypass graft; PCI, percutaneous
coronary intervention.
TABLE 2 Baseline lesion characteristics (Adjudicated by the
Angiographic Core Lab)
Synergy 48 N = 100 patients





Lesion length (mm) 35.34 ± 7.15 (98)
≤34 mm 40.8% (40)
>34 – 40 mm 32.7% (32)
>40 – 44 mm 17.3% (17)
>44 mm 9.2% (9)
Reference vessel diameter (mm) 2.72 ± 0.44 (100)
3.0 mm 76.0% (76)
3.0 – 3.5 mm 20.0% (20)
>3.5 mm 4.0% (4)
Minimum lumen diameter (mm) 0.78 ± 0.43 (100)
% diameter stenosis 71.23 ± 14.98 (100)
Pre-TIMI flow grade 3 89.0% (89)
Modified AHA/ACC B2/C 100.0% (100)
Calcification, moderate/severe 30.0% (30)
Note: Values are mean ± SD or % (n), Intent-to-treat analysis.
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reported in prior studies evaluating the performance of stents up to
38 mm in size.7,23 In the RESOLUTE 38 mm sub-study23 evaluating
the use of the 38 mm durable polymer Resolute zotarolimus-eluting
stent among real-world patients, the rate of 1-year TVR was low
(2.7%), with no patients developing ST after 30 days (0.9%). The study
met the primary endpoint of 1-year TLF (5.4%), which was signifi-
cantly below the prespecified performance goal of 19.0%.23 Compara-
ble rates of TVR (3.9%) and ST (1.0%) were observed at 1-year in the
real-world P38 registry7 that enrolled patients treated with at least
one 38 mm durable polymer Xience Prime everolimus-eluting stent
(EES). Despite the use of a very long stent, the absence of ST in the
present study population suggests that the bioabsorbable polymer
together with the optimal combination of platinum-chromium metal
alloy, thinner struts and everolimus coating play an important role in
defining the safety of the SYNERGY 48 mm stent. Also, everolimus is
eluted in 90 days and bioabsorbable PLGA polymer is completely
degraded within 4 months leaving behind a bare metal platform,
which may help prevent the occurrence of late/very late ST.9
Recently conducted trials studying the use of very long stents have
reported good clinical outcomes in retrospective analyzes of real-world
population undergoing PCI. Jurado-Roman et al.3 compared the use of
very long stents (≥40 mm), including the new generation SYNERGY
48 mm size, to overlapping stents. The rates of TLR were significantly
lower with the use of one very long stent (0.9%) versus overlapping
stents (4.7%; p = 0.01). No between-group differences in cardiac death,
acute MI or ST were observed at 20 months. Also, procedure and fluo-
roscopy time were lower with the use of very long stents, and required
less contrast volume.3 A single center study evaluating the performance
of 48 mm Xience Expedition durable polymer EES showed favorably
low incidence of major adverse cardiac events (3.3%) and ST (1.3%) at
1-year.24 Two-year TLF rate in an observational registry for patients
treated with a single long 48 mm Xience Expedition stent was 5.3% and
probable ST was 0.9%.25 It must be noted that between the 1-2-year
timeframe, TLF occurred in only one additional patient treated with the
48 mm SYNERGY stent (2-year TLF: 5.0%), which was primarily driven
by MI related to the target vessel. There were no additional cardiac
deaths or the occurrent of very late ST. Acknowledging the limitations
of comparing trials, the event rates in previous studies align with those
observed in EVOLVE 48; although the rate of ST appears to be lower in
patients treated with 48 mm SYNERGY stent.3,24,25
Honda et al.26 evaluated the performance of both durable and bio-
absorbable polymer stents that were ultra-long (>50 mm) and long (20–
50 mm), and compared outcomes to those of short stents (<20 mm). The
TABLE 3 Procedural and postprocedural characteristics
Synergy 48 N = 100
patients N = 100 lesions
Procedural characteristics
Technical success 100.0% (100)
Clinical procedural success 100.0% (100)
Time from sheath placement to last
guide catheter removal (min)
52.47 ± 24.29 (100)
Stents per patient
Total stent length implanteda, mm 50.96 ± 7.25 (100)
Predilatation 99.0% (99)
Postdilatation 99.0% (99)
Max pressure overall (atm) 19.02 ± 3.82 (100)
Postprocedural characteristics
Reference vessel diameter (mm) 2.74 ± 0.43 (99)
Minimum lumen diameter (mm)
In-stent 2.47 ± 0.40 (99)
In-segment 2.18 ± 0.44 (99)
Acute gain (mm)
In-stent 1.68 ± 0.51 (99)
In-segment 1.39 ± 0.52 (99)
% diameter stenosis
In-stent 9.74 ± 7.19 (99)
In-segment 20.83 ± 8.69 (99)
Note: Values are mean ± SD or % (n).
aIncludes the 48 mm study stent and any nonstudy stents implanted;
Intent-to-treat analysis.
F IGURE 2 Antiplatelet medications through 2-year follow-up.
Aspirin and dual antiplatelet therapy (DAPT) use for the SYNERGY
48 mm stent at discharge, 30 days, 6 months, 1 and 2 years poststent
implantation
F IGURE 3 Primary endpoint of target lesion failure (TLF) at
1 year. TLF in the SYNERGY 48 mm intent-to-treat and perprotocol
patient populations was compared to a 19.5% performance goal. One-
sided 95.0% upper confidence bound (UCB*) is indicated by the error
bar. p-value was calculated using the Clopper–Pearson Exact test
KARMPALIOTIS ET AL. 5
F IGURE 4 Kaplan–Meier curves for target lesion failure (TLF) and individual components through 2 years. (A) TLF, (B) target vessel-related
myocardial infarction (TV-MI), and (C) target lesion revascularization (TLR), and (D) cardiac death. CI, confidence intervals
TABLE 4 Clinical endpoints through
2 years
1-year(N = 100) 2 years (N = 100)
Events Rate 95% CI Rate 95% CI
Death 5.0% (5) [1.6%, 11.3%] 5.0% (5) [1.6%, 11.3%]
Cardiac death 1.0% (1) [0.0%, 5.4%] 1.0% (1) [0.0%, 5.4%]
Noncardiac death 4.0% (4) [1.1%, 9.9%] 4.0% (4) [1.1%, 9.9%]
Myocardial infarction 2.0% (2) [0.2%, 7.0%] 4.0% (4) [1.1%, 9.9%]
Q-wave 0.0% (0) [0.0%, 3.6%] 1.0% (1) [0.0%, 5.4%]
Related to target vessel 0.0% (0) [0.0%, 3.6%] 0.0% (0) [0.0%, 3.6%]
Non-Q-wave 2.0% (2) [0.2%, 7.0%] 3.0% (3) [0.6%, 8.5%]
Related to target vessel 2.0% (2) [0.2%, 7.0%] 3.0% (3) [0.6%, 8.5%]
Target vessel revascularization 1.0% (1) [0.0%, 5.4%] 1.0% (1) [0.0%, 5.4%]
PCI 1.0% (1) [0.0%, 5.4%] 1.0% (1) [0.0%, 5.4%]
CABG 0.0% (0) [0.0%, 3.6%] 0.0% (0) [0.0%, 3.6%]
Target lesion revascularization 1.0% (1) [0.0%, 5.4%] 1.0% (1) [0.0%, 5.4%]
PCI 1.0% (1) [0.0%, 5.4%] 1.0% (1) [0.0%, 5.4%]
CABG 0.0% (0) [0.0%, 3.6%] 0.0% (0) [0.0%, 3.6%]
Non-TLR TVR 1.0% (1) [0.0%, 5.4%] 1.0% (1) [0.0%, 5.4%]
PCI 1.0% (1) [0.0%, 5.4%] 1.0% (1) [0.0%, 5.4%]
CABG 0.0% (0) [0.0%, 3.6%] 0.0% (0) [0.0%, 3.6%]
Target lesion failure 4.0% (4) [1.1%, 9.9%] 5.0% (5) [1.6%, 11.3%]
Target vessel failure 4.0% (4) [1.1%, 9.9%] 5.0% (5) [1.6%, 11.3%]
ARC stent thrombosis 0.0% (0) [0.0%, 3.6%] 0.0% (0) [0.0%, 3.6%]
Note: Values are % (n), Intent-to-treat analysis.
Abbreviation: CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.
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rate of TLR at 1-year was significantly higher in the ultra-long group
(13.5%) compared to the long (7.2%) and short (6.0%) DES groups
(p = 0.001). No significant differences were noted between groups for
individual cardiac events and ST. These data support the safety and effi-
cacy of long stents up to 50 mm in size.26 Furthermore, the safety and
effectiveness of bioabsorbable polymer DES for treatment of long
(≥25 mm) coronary lesions has been established in the LongDrug-Eluting
Stent (LONG-DES) V multicenter, prospective randomized controlled
trial.2 The primary endpoint of 9-month angiographic in-segment late
luminal loss was comparable between biolimus-eluting bioabsorbable
Nobori versus everolimus-eluting durable Promus Element stents (0.14
± 0.38 versus 0.11 ± 0.37 mm; p = 0.03 for a noninferiority margin of
0.11, p = 0.45 for superiority). There were no significant between-group
difference in the rates of TLF (16.3% versus 16.5%; p = 0.97), TLR (3.3%
versus 2.0%; p = 0.44) and ST (1.2% versus 0.0%; p = 0.12).2 Although
not directly comparable due to differences in the inclusion/exclusion
criteria, low revascularization and ST rates were observed in the present
study despite the use of longer implanted stent sizes than in LONG-DES-
V, validating the safety and performance of the SYNERGY48 mmstent.
5 | STUDY LIMITATIONS
The 2-year outcomes from the EVOLVE 48 study demonstrate low
rates of adverse cardiac events, with no ST. However, this was a non-
randomized trial that did not include an active comparator or a control
group and comparing these results to clinical outcomes with other
contemporary DES is challenging. The relatively small sample size may
have limited the ability to assess rare clinical adverse outcomes, such
as ST. Also, this study was not powered to evaluate individual clinical
endpoints at 2 years. Patients with very high lesion complexity were
not enrolled, and therefore this study does not fully represent real-
world patients. In addition, adequate predilatation was specified in the
protocol and postdilatation was optional yet performed in almost all
implanted DES. As such, postdilatation may have significantly contrib-
uted to the high technical and procedural success rates, as well as the
excellent 2-year clinical outcomes, and should therefore be consid-
ered when treating long coronary lesions. Finally, use of intravascular
imaging or ancillary devices was neither prespecified nor captured in
the present study; nevertheless, it should be considered in all complex
PCI cases with long lesions.
6 | CONCLUSIONS
The EVOLVE 48 study demonstrated good procedural and clinical out-
comes among patients undergoing PCI for long lesions and met the
prespecified primary endpoint at 12 months, with no incidence of ST
through 2 years. These data support the safety and efficacy of the SYN-
ERGY 48 mmEES for the treatment of long coronary artery lesions.
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